dalteparin has been researched along with Paraneoplastic Syndromes in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Paraneoplastic Syndromes: In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Züger, M | 1 |
| Demarmels Biasiutti, F | 1 |
| Wuillemin, WA | 1 |
| Furlan, M | 1 |
| Lämmle, B | 1 |
| Bergqvist, D | 1 |
| Walsh-McMonagle, D | 1 |
| Green, D | 1 |
| Korenkov, M | 1 |
| Depta, A | 1 |
| Kentner, R | 1 |
| Beck, J | 1 |
| Junginger, T | 1 |
1 review available for dalteparin and Paraneoplastic Syndromes
| Article | Year |
|---|---|
Venous thromboembolism in cancer patients: expanding horizons.
Topics: Antineoplastic Agents; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular- | 2002 |
3 other studies available for dalteparin and Paraneoplastic Syndromes
| Article | Year |
|---|---|
Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome.
Topics: Aged; Anticoagulants; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Humans; Injections, S | 1997 |
Low-molecular-weight heparin in the management of Trousseau's syndrome.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Neoplasms; Paraneoplastic Synd | 1997 |
[Paraneoplastic lupus anticoagulans syndrome].
Topics: Anticoagulants; Antiphospholipid Syndrome; Dalteparin; Female; Fibrinolytic Agents; Follow-Up Studie | 2005 |